## Abstract The identification of erythropoietin receptors (EpoR) on cancer cells has caused concern, since it implies the possibility that treatment of cancer patients with erythropoietin (Epo) and related agents with demonstrable antiapoptotic activity could enhance cancer growth and progression.
Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain
✍ Scribed by Anna-Leena Sirén; Friederike Knerlich; Wolfgang Poser; Christoph H. Gleiter; Wolfgang Brück; Hannelore Ehrenreich
- Publisher
- Springer-Verlag
- Year
- 2001
- Tongue
- English
- Weight
- 412 KB
- Volume
- 101
- Category
- Article
- ISSN
- 0001-6322
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND. Children with high‐risk neuroblastomas (NB) potentially may benefit from treatment with recombinant human erythropoietin (Epo). Epo is a stimulator of erythropoiesis, acting through its receptor (EpoR). The objective of the current study was to evaluate expression levels
## Abstract ## Background Numerous reports on recombinant human erythropoietin (rHuEPO, epoetin alfa) treatment of cancer‐related anemia in adult patients have been published to date. These have shown that epoetin increases hemoglobin levels, significantly ameliorates symptoms of anemia, and impro